Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment.
Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment.
复制标题
纤维蛋白原样蛋白 2：胶质母细胞瘤治疗的潜在分子靶点。
DOI：
10.1080/14728222.2019.1628220
复制
发表时间：
2019
影响因子：
5.8
通讯作者：
Rao,Ganesh
中科院分区：
文献类型：
--
作者：
Patel,Rajan;Traylor,JeffreyI;Latha,Khatri;Heimberger,AmyB;Li,Shulin;Rao,Ganesh
多形性胶质母细胞瘤（GBM）是成人中最常见和最具侵袭性的原发性脑肿瘤。在过去的二十年中，已经开发了许多新的多模式治疗，但预后不良在很大程度上保持不变。最近的研究表明，免疫抑制在GBM进展中起主要作用。虽然需要更多的研究来充分理解允许胶质瘤逃避免疫监视的免疫抑制机制，但已经确定了一些可能具有治疗前景的关键分子。我们研究了纤维蛋白原样蛋白2。该纤维蛋白原家族成员的分泌形式具有独特的免疫抑制功能。FGL 2在成人中的表达主要在T细胞、内皮细胞和肿瘤细胞中。它在这些组织中的独特定位使其在微环境中发挥重要作用。在胶质母细胞瘤中，它似乎促进导致肿瘤进展的免疫抑制。
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Over the last two decades many new multimodal therapeutic have been developed but the poor prognosis has remained largely unchanged. Recent research shows that immunosuppression plays a major role in GBM progression. While additional studies are needed to fully understand the immunosuppressive mechanisms that permit gliomas to evade immune surveillance, some key molecules have been identified that may hold therapeutic promise. We have investigated Fibrinogen-like Protein 2. The secreted form of this member of the fibrinogen family has unique immunosuppressive functions. Expression of FGL2 in the adult is primarily in T cells, endothelial and tumor cells. Its unique localization to these tissues gives it a prominent role in the microenvironment. In glioblastoma, it appears to facilitate immunosuppression which results in tumor progression.